End points evaluated were maximum preinjection IOP during the 24-month treatment period ; any occurrence of absolute preinjection IOP of 21 mmHg or more , 25 mmHg or more , or 30 mmHg or more ; any occurrence of IOP increase of 6 mmHg or more , 8 mmHg or more , or 10 mmHg or more from baseline ; any combination of IOP increase of 6 mmHg or more or 8 mmHg or more from baseline with concurrent absolute preinjection IOP of 21 mmHg or more or 25 mmHg or more ; glaucoma-related adverse events ; new glaucoma medications used for 45 days or more ; and glaucoma filtration or laser surgeries .